MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and-independent mechanisms

British Journal of Cancer

Volumn 112, Issue 9, 2015, Pages 1480-1490

  Amankwatia, E B ^a   Chakravarty, P ^b   Carey, F A ^a   Weidlich, S ^a   Steele, R J C ^a   Munro, A J ^a   Wolf, C R ^a   Smith, G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

chemotherapy; colorectal adenoma; colorectal cancer; KRAS; microRNA; miR 224

Indexed keywords

ANTAGOMIR; B RAF KINASE; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MICRORNA; MICRORNA 193B; MICRORNA 224; MICRORNA 32 5P; MICRORNA 323 3P; MICRORNA 324 3P; MICRORNA 331 5P; MICRORNA 339 3P; MICRORNA 365; MICRORNA 374; MICRORNA 449B; MICRORNA 487A; MICRORNA 491 5P; MICRORNA 494; MICRORNA 501; MICRORNA 532 5P; MICRORNA 574 3P; MICRORNA 671 3P; MICRORNA 744; MICRORNA 99B; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; KRAS PROTEIN, HUMAN; MESSENGER RNA; MIRN224 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

3T3 CELL LINE; ALLELE; ANTISENSE THERAPY; ARTICLE; BIOINFORMATICS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X CHROMOSOME; ADENOMA; ANIMAL; APOPTOSIS; CANCER STAGING; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MOUSE; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION;

ADENOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICRORNAS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIH 3T3 CELLS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84928655975     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.125     Document Type: Article

References (73)

1. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, Garciá JJC, Scott L, Fyfe N, Murray GI, Kolch W. (2006). Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol 24: 5672-5679
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. (2008). Wild-Type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634
3. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M. (2009). Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374
4. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, Garciá-Foncillas J. (2006). Identification by real-Time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-Tumoral tissues. Mol Cancer 5: 29
5. Barbacid M. (1990). ras oncogenes: their role in neoplasia. Eur J Clin Invest 20: 225-235
6. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297
7. Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, Rashid A, Calin GA, Luthra R, Hamilton SR. (2011). Complex patterns of altered microRNA expression during the adenoma-Adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res 17: 7283-7293
8. Battle TE, Lynch RA, Frank DA. (2006). Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res 66: 3649-3657
9. Benjamini Y, Hochberg Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57: 289-300
10. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. (2008). KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCR) with FOLFOX with or without cetuximab: the OPUS experience. ASCO Meet Abstr 26: 4000
11. Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JHM, Byrne MM. (2013). Identification of circulating microRNAs in HNF1A-MODY carriers. Diabetologia 56: 1743-1751
12. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
13. Cancer Research UK. (2014). Bowel cancer key facts http://www. cancerresearchuk.org/cancer-info/cancerstats/keyfacts/bowel-cancer/#survival. accessed: 29 June 2014
14. Chang KH, Miller N, Kheirelseid EAH, Lemetre C, Ball GR, Smith MJ, Regan M, McAnena OJ, Kerin MJ. (2011). MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 26: 1415-1422
15. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, Zhang J, Zhang C-Y. (2009). Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28: 1385-1392
16. Cheng T, Wang L, Li Y, Huang C, Zeng L, Yang J. (2013). Differential microRNA expression in renal cell carcinoma. Oncol Lett 6: 769-776
17. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJC. (2005). The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54: 1283-1286
18. Earle JSL, Luthra R, Romans A, Abraham R, Ensor J, Yao H, Hamilton SR. (2010). Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J Mol Diagn 12: 433-440
19. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R, Slaby O. (2012). Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16: 2655-2666
20. Fu J, Tang W, Du P, Wang G, Chen W, Li J, Zhu Y, Gao J, Cui L. (2012). Identifying microRNA-mRNA regulatory network in colorectal cancer by a combination of expression profile and bioinformatics analysis. BMC Syst Biol 6: 68
21. Fujioka S, Nakamichi I, Esaki M, Asano K, Matsumoto T, Kitazono T. (2014). Serum microRNA levels in patients with Crohns disease during induction therapy by infliximab. J Gastroenterol Hepatol 29: 1207-1214
22. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80
23. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH. (2012). Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-Throughput sequencing. PloS One 7: e34150
24. Huang L, Dai T, Lin X, Zhao X, Chen X, Wang C, Li X, Shen H, Wang X. (2012). MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. Biochem Biophys Res Commun 425: 127-133
25. Illemann M, Bird N, Majeed A, Sehested M, Laerum OD, Lund LR, Danø K, Nielsen BS. (2006). MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Mol Cancer Res 4: 293-302
26. Kanaan Z, Roberts H, Eichenberger MR, Billeter A, Ocheretner G, Pan J, Rai SN, Jorden J, Williford A, Galandiuk S. (2013). A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann Surg 258: 400-408
27. Klampfer L, Swaby L-A, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. (2005). Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis. Oncogene 24: 3932-3941
28. Kuo T-Y, Hsi E, Yang I-P, Tsai P-C, Wang J-Y, Juo S-HH. (2012). Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PloS One 7: e31587
29. Lamouille S, Xu J, Derynck R. (2014). Molecular mechanisms of epithelialmesenchymal transition. Nat Rev Mol Cell Biol 15: 178-196
30. Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM, Smith G, Wolf CR, Carey FA, Steele RJC. (2003). Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res 63: 4656-4661
31. Leslie A, Stewart A, Baty DU, Mechan D, McGreavey L, Smith G, Wolf CR, Sales M, Pratt NR, Steele RJC, Carey FA. (2006). Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility. Genes Chromosomes Cancer 45: 126-135
32. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20
33. Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, Lei L, Chen Y, Mao B, Jiang M, Li J, Wang D, Wang G. (2014). miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol 29: 835-842
34. Li Q, Wang G, Shan J-L, Yang Z-X, Wang H-Z, Feng J, Zhen J-J, Chen C, Zhang Z-M, Xu W, Luo X-Z, Wang D. (2010). MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 25: 164-171
35. Liao W-T, Li T-T, Wang Z-G, Wang S-Y, He M-R, Ye Y-P, Qi L, Cui Y-M, Wu P, Jiao H-L, Zhang C, Xie Y-J, Wang J-X, Ding Y-Q. (2013). microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res 19: 4662-4672
36. Liévre A, Bachet J-B, Le Corre D, Boige V, Landi B, Emile J-F, Coté J-F, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995
37. Ma D, Tao X, Gao F, Fan C, Wu D. (2012). miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 4: 483-488
38. Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balagué O, Garcia-Foncillas J. (2008). Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res 18: 823-833
39. Mosakhani N, Sarhadi VK, Borze I, Karjalainen-Lindsberg M-L, Sundström J, Ristamäki R, Osterlund P, Knuutila S. (2012). MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer 51: 1-9
40. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M. (2009). Over-And under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075
41. National Health Service. (2014). NHS Bowel Cancer Screening Programme, 2014 http://www.cancerscreening.nhs.uk/bowel/accessed: 29 July 2014
42. Oberg AL, French AJ, Sarver AL, Subramanian S, Morlan BW, Riska SM, Borralho PM, Cunningham JM, Boardman LA, Wang L, Smyrk TC, Asmann Y, Steer CJ, Thibodeau SN. (2011). miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PloS One 6: e20465
43. Olaru AV, Yamanaka S, Vazquez C, Mori Y, Cheng Y, Abraham JM, Bayless TM, Harpaz N, Selaru FM, Meltzer SJ. (2013). MicroRNA-224 negatively regulates p21 expression during late neoplastic progression in inflammatory bowel disease. Inflamm Bowel Dis 19: 471-480
44. Pierre S, Bats A-S, Coumoul X. (2011). Understanding SOS (Son of Sevenless). Biochem Pharmacol 82: 1049-1056
45. R Development Core Team. (2008). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria
46. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, Scalia M, Cappellani A, Vasquez E, Lanzafame S, Basile F, Di Pietro C, Purrello M. (2010). Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Mol Cancer Ther 9: 3396-3409
47. Reid JF, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C, Zanutto S, Perrone F, Camerini T, Gallino G, Verderio P, Leo E, Pilotti S, Gariboldi M, Pierotti MA. (2012). miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res 10: 504-515
48. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KAT, Morlan BW, Riska SM, Boardman LA, Cunningham JM, Subramanian S, Wang L, Smyrk TC, Rodrigues CMP, Thibodeau SN, Steer CJ. (2009). Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9: 401
49. Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K, ørntoft TF, Andersen CL. (2012). Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene 31: 2750-2760
50. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DLW, Au GKH, Liu C-G, Calin GA, Croce CM, Harris CC. (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425-436
51. Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, DOnorio de Meo P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N. (2012). Transcriptional regulation of miR-224 upregulated in human HCCs by NFkB inflammatory pathways. J Hepatol 56: 855-861
52. Scottish Bowel Screening Programme. (2014). Why is screening important? http://www.bowelscreening.scot.nhs.uk/why-is-screening-important. accessed: 29 June 2014
53. Scottish Intercollegiate Guidelines Network. (2011). Diagnosis and management of colorectal cancer. SIGN: Edinburgh, 2014. Available at http://www.sign.ac.uk
54. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88
55. Smith G, Bounds R, Wolf H, Steele RJC, Carey FA, Wolf CR. (2010). Activating K-Ras mutations outwith hotspot codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 102: 693-703
56. Smith G, Carey FA, Beattie J, Wilkie MJV, Lightfoot TJ, Coxhead J, Garner RC, Steele RJC, Wolf CR. (2002). Mutations in APC, Kirsten-ras, and p53-Alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 99: 9433-9438
57. Smith G, Ng MTH, Shepherd L, Herrington CS, Gourley C, Ferguson MJ, Wolf CR. (2012). Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer. Br J Cancer 107: 1327-1336
58. Smyth GK. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3
59. Song G, Gu L, Li J, Tang Z, Liu H, Chen B, Sun X, He B, Pan Y, Wang S, Cho WC. (2014). Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients. Ann Hematol 93: 1735-1743
60. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. (2001). Use of isogenic human cancer cells for high-Throughput screening and drug discovery. Nat Biotechnol 19: 940-945
61. Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K, Aoki T, Ueda S, Takanashi M, Kuroda M. (2011). miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 102: 2264-2271
62. Wang Y, Lee ATC, Ma JZI, Wang J, Ren J, Yang Y, Tantoso E, Li K-B, Ooi LLPJ, Tan P, Lee CGL. (2008). Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem283: 13205-13215
63. Wang Y, Ren J, Gao Y, Ma JZI, Toh HC, Chow P, Chung AYF, Ooi LLPJ, Lee CGL. (2013). MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PloS One 8: e68744
64. Wang Y, Toh HC, Chow P, Chung AYF, Meyers DJ, Cole PA, Ooi LLPJ, Lee CGL. (2012). MicroRNA-224 is up-regulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J 26: 3032-3041
65. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ. (2010). Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11: 50-54
66. Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, Carey FA, Steele RJC, Wolf CR, Miele G, Smith G. (2011). Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Br J Cancer 105: 246-254
67. Wu CW, Ng SC, Dong Y, Tian L, Ng SSM, Leung WW, Law WT, Yau TO, Chan FKL, Sung JJY, Yu J. (2014). Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res 20: 2994-3002
68. Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C, Wu M. (2013). Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology 145: 853-864.e9
69. Zhang G-J, Zhou H, Xiao H-X, Li Y, Zhou T (2013) Up-regulation of miR-224 promotes cancer cell proliferation and invasion and predicts relapse of colorectal cancer. Cancer Cell Int 13: 104
70. Zhang JX, Mai SJ, Huang XX, Wang FW, Liao YJ, Lin MC, Kung HF, Zeng YX, Xie D (2014) MiR-29c mediates epithelial-To-mesenchymal transition in human colorectal carcinoma metastasis via PTP4A and GNA13 regulation of b-catenin signaling. Ann Oncol 25: 2196-2204
71. Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK, Sung JJ, Yu J (2014) microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol Cancer 13: 124
72. Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K (2013) Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-Apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 28: 565-575
73. Zhou T, Zhang G, Liu Z, Xia S, Tian H. (2013). Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis 28: 19-24